EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cue Biopharma's EBITDA for the
three
months ended in Mar. 2026 was $-4.25 Mil. Cue Biopharma's Revenue for the
three
months ended in Mar. 2026 was $5.69 Mil. Therefore, Cue Biopharma's EBITDA margin for the quarter that ended in Mar. 2026 was -74.66%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cue Biopharma EBITDA Margin % Related Terms
Cue Biopharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cue Biopharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CUE vs TELO, ACET, AARD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Cue Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cue Biopharma (CUE) has a EBITDA Margin % of -74.66% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cue Biopharma and its competitors. According to the industry distribution chart, Cue Biopharma ranks #446 out of 945 companies in the Biotechnology industry, placing it in the top 47.2%.
Is Cue Biopharma's EBITDA Margin % too high?
Cue Biopharma's current EBITDA Margin % is -74.66%. Based on the distribution chart, Cue Biopharma ranks #446 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cue Biopharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's EBITDA Margin % compare to TELO and ACET?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #446 out of 945 companies for EBITDA Margin %. This puts Cue Biopharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current EBITDA Margin % is -74.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.11, compared to a current price of $26.01 — trading 58.1% below its estimated fair value. The current EBITDA Margin % is -74.66%. Cue Biopharma's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cue Biopharma (CUE), the current EBITDA Margin % is -74.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cue Biopharma (CUE) Overvalued in 2026?
Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued.
The current stock price of $26.01 is trading 58.1% below its estimated GF Value™ of $62.11.
GuruFocus considers Cue Biopharma to be Possible Value Trap.
Key valuation signals for CUE:
EBITDA Margin %: -74.66%
GF Value™: $62.11 vs. price of $26.01 (58.1% below fair value)
No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
59GF Score
Get the complete analysis for CUE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUE has been successfully added to your 
